Table 1.

Combining multiple checkpoint blockade antibodies with conventional cancer vaccines.

Clinical Trial #	Trial Name	Indication	Status	Trial Phase	n	Treatments
NCT03784040	Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer—a Combination Immunotherapy Phase Ib Study	Gastric cancer	Recruiting	I	40	OTSGC-A24 Nivolumab Ipilimumab
NCT04117087	Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer	Colorectal cancer Pancreatic cancer	Recruiting	I	30	KRAS peptide vaccine Nivolumab Ipilimumab
NCT04248569	DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma	Fibrolamellar hepatocellular carcinoma	Recruiting	I	12	DNAJB1-PRKACA peptide vaccine Nivolumab Ipilimumab
NCT03164772	Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC	Metastatic non-small-cell lung cancer	Recruiting	I/II	56	BI 1361849 Durvalumab Tremelimumab

#: NCT: clinicaltrials.gov identification number. OTSGC-A24: peptide cancer vaccine-targeting tumor antigens FOXM1, DEPDC1, KIF20A, URLC10, VEGFR1. KRAS: Kirsten rat sarcoma virus oncogene. DNAB1-PRCACA: fusion kinase that is major driver of fibrolamellar hepatocellular carcinoma. BI 1361849: mRNA vaccine targeting tumor-associated antigens MUC1, survivin, NY-ESO-1, MAGE-C2, MAGE-C1.